SprayClinical Overview
Mometasone Furoate Aqueous Nasal Spray (0.05% w/v / 50mcg per actuation) is a topically active synthetic glucocorticoid on the WHO Model List of Essential Medicines. It exhibits high topical anti-inflammatory potency on nasal mucosa with undetectable systemic bioavailability (<0.1%), downregulating pro-inflammatory cytokines and allergic cellular infiltration. Indicated for treatment and prophylaxis of seasonal and perennial allergic rhinitis in adults and children >=2 years, and treatment of nasal polyps in adults >=18 years.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Allergic rhinitis: 2 sprays in each nostril once daily (morning); reduce to 1 spray per nostril daily once controlled. Nasal polyps: 2 sprays in each nostril twice daily. Shake well before each use. Point spray away from the nasal septum.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Epistaxis, headache, pharyngitis, nasal burning, nasal ulceration. Rare/Severe: Nasal septal perforation and localized fungal infections.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Direct spray away from nasal septum. Inspect nasal passages periodically during prolonged use. Unmatched systemic safety profile with zero hypothalamic-pituitary-adrenal (HPA) axis suppression.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, pulmonological diagnosis, or respiratory management recommendations. Inhalation therapies and allergy medications should be used strictly under the guidance of a qualified pulmonologist or registered medical practitioner.
Hydroquinone 2%, Mometasone 0.1% and Tretinoin 0.025% Cream
Hydroquinone, Tretinoin, and Fluocinolone Acetonide is the gold-standard Triple Combination Cream (Kligman's formula) for refractory melasma. Hydroquinone (2-4%) competitively inhibits tyrosinase, blocking melanin pigment synthesis; Tretinoin (0.05%) accelerates epidermal turnover and keratinocyte shedding, facilitating hydroquinone penetration and dispersing melanin; and Fluocinolone Acetonide (0.01%), a mild-to-moderate topical corticosteroid, suppresses melanocyte inflammation and counteracts the irritant dermatitis of hydroquinone and tretinoin. Indicated for the short-term moderate-to-severe melasma of the face.
Mometasone Furoate Cream 0.1%
Mometasone Furoate (0.1% w/w cream/ointment) is a high-potency (Class II) synthetic topical corticosteroid on the WHO Model List of Essential Medicines. It features a high therapeutic index, providing robust anti-inflammatory and anti-pruritic activity with significantly lower systemic absorption and cutaneous atrophogenic potential than older fluorinated steroids. Indicated for relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, including atopic dermatitis and psoriasis.
Indacaterol 150mcg + Mometasone Furoate 160mcg Powder for Inhalation
Indacaterol (150mcg) and Mometasone Furoate (80mcg/160mcg/320mcg Powder for Inhalation) is an advanced once-daily LABA and inhaled corticosteroid combination. Indacaterol is an ultra-long-acting beta-2 agonist (ultra-LABA) providing 24-hour bronchodilator coverage from a single dose; mometasone furoate provides powerful glucocorticoid anti-inflammatory action with negligible systemic oral bioavailability (<1%). Indicated for once-daily maintenance treatment of asthma in adults and adolescents inadequately controlled with ICS/LABA combinations.
Indacaterol 150mcg + Mometasone Furoate 320mcg Powder for Inhalation
Indacaterol (150mcg) and Mometasone Furoate (80mcg/160mcg/320mcg Powder for Inhalation) is an advanced once-daily LABA and inhaled corticosteroid combination. Indacaterol is an ultra-long-acting beta-2 agonist (ultra-LABA) providing 24-hour bronchodilator coverage from a single dose; mometasone furoate provides powerful glucocorticoid anti-inflammatory action with negligible systemic oral bioavailability (<1%). Indicated for once-daily maintenance treatment of asthma in adults and adolescents inadequately controlled with ICS/LABA combinations.